14:48 : Despite Gene Patent Victory, Myriad Genetics Faces Challenges -
Myriad Genetics plans to rely less on patents and more on trade secrets #x2014; leveraging its huge database on gene mutations to defend its franchise in testing for breast cancer risk.
09:19 : Myriad Genetics Patent Appeal Case Arguments Begin April 4 -
Oral arguments for the Myriad Genetics, Inc. (NASDAQ: MYGN) appeals case is set to begin April 4 with a possible written decision in June 2011, RBC Capital Markets said.